NO20006633L - Preparat som omfatter <beta>-hydroksy-<beta>-metylsmörsyre og minst én aminosyre, og fremgangsmåter for anvendelse - Google Patents

Preparat som omfatter <beta>-hydroksy-<beta>-metylsmörsyre og minst én aminosyre, og fremgangsmåter for anvendelse

Info

Publication number
NO20006633L
NO20006633L NO20006633A NO20006633A NO20006633L NO 20006633 L NO20006633 L NO 20006633L NO 20006633 A NO20006633 A NO 20006633A NO 20006633 A NO20006633 A NO 20006633A NO 20006633 L NO20006633 L NO 20006633L
Authority
NO
Norway
Prior art keywords
beta
preparations
hydroxy
methods
amino acid
Prior art date
Application number
NO20006633A
Other languages
English (en)
Other versions
NO329914B1 (no
NO20006633D0 (no
Inventor
Steven L Nissen
Naji M Abumrad
Original Assignee
Univ Iowa State Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22292520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20006633(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Iowa State Res Found Inc filed Critical Univ Iowa State Res Found Inc
Publication of NO20006633D0 publication Critical patent/NO20006633D0/no
Publication of NO20006633L publication Critical patent/NO20006633L/no
Publication of NO329914B1 publication Critical patent/NO329914B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
NO20006633A 1998-06-23 2000-12-22 Preparat som omfatter <beta>-hydroksy-<beta>-metylsmorsyre, L-glutamin og L-arginin, og anvendelse av preparatet til fremstilling av et ernaeringspreparat NO329914B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/102,941 US6031000A (en) 1998-06-23 1998-06-23 Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
PCT/US1999/014097 WO1999066917A2 (en) 1998-06-23 1999-06-23 Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid

Publications (3)

Publication Number Publication Date
NO20006633D0 NO20006633D0 (no) 2000-12-22
NO20006633L true NO20006633L (no) 2001-02-20
NO329914B1 NO329914B1 (no) 2011-01-24

Family

ID=22292520

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20006633A NO329914B1 (no) 1998-06-23 2000-12-22 Preparat som omfatter <beta>-hydroksy-<beta>-metylsmorsyre, L-glutamin og L-arginin, og anvendelse av preparatet til fremstilling av et ernaeringspreparat
NO20101440A NO332374B1 (no) 1998-06-23 2010-10-18 Preparat som omfatter beta-hydroksy-beta-metylsmorsyre, L-arginin og L-lysin, og anvendelse av preparatet til fremstilling av ernaeringspreparater for bruk til dyr

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20101440A NO332374B1 (no) 1998-06-23 2010-10-18 Preparat som omfatter beta-hydroksy-beta-metylsmorsyre, L-arginin og L-lysin, og anvendelse av preparatet til fremstilling av ernaeringspreparater for bruk til dyr

Country Status (12)

Country Link
US (1) US6031000A (no)
EP (1) EP1089726B1 (no)
JP (2) JP5064609B2 (no)
AU (1) AU756353B2 (no)
CA (1) CA2334761C (no)
DE (1) DE69901396T2 (no)
DK (1) DK1089726T3 (no)
ES (1) ES2177293T3 (no)
NO (2) NO329914B1 (no)
NZ (1) NZ508395A (no)
PL (1) PL195623B1 (no)
WO (1) WO1999066917A2 (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3362350B2 (ja) * 1997-10-16 2003-01-07 味の素株式会社 反芻動物の肥育方法
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) * 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US6812249B2 (en) * 2003-03-04 2004-11-02 Sal Abraham Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
EP1973426A2 (en) * 2005-11-03 2008-10-01 Southwest Immunology Inc. Compositions for preventing and reducing delayed onset muscle soreness
WO2007064618A1 (en) * 2005-11-30 2007-06-07 Nestec S.A. Methods for the treatment of muscle loss
CA2632262C (en) 2005-12-19 2015-04-07 Abbott Laboratories Method of using .beta.-hydroxy-.beta.-methylbutyrate
US8324175B2 (en) 2006-02-16 2012-12-04 Young Hee Ko Compositions and methods for the treatment of cancer
US7754693B2 (en) * 2006-02-16 2010-07-13 Young Hee Ko Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
US9539224B2 (en) 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9770424B2 (en) * 2008-12-09 2017-09-26 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
EP2381784B1 (en) 2008-12-09 2018-07-11 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
JP6068803B2 (ja) * 2009-01-29 2017-01-25 コー，ヤング，ヒー 癌治療用組成物及び癌治療方法
EP2289555A1 (en) * 2009-08-24 2011-03-02 OrgaNext Research B.V. Method of treating frailty
PT2512236T (pt) * 2009-12-18 2016-12-29 Metabolic Tech Inc Método aperfeiçoado de administração de beta-hidroxi-beta-metilbutirato (hmb)
BR112012017690A2 (pt) 2010-01-29 2015-09-01 Abbott Lab Emulsões nutricionais compreendendo hmb de cálcio
EP2461704B1 (en) 2010-01-29 2013-10-09 Abbott Laboratories Aseptically packaged nutritional liquids comprising hmb
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
PH12014500198A1 (en) 2011-07-15 2017-02-10 Nusirt Sciences Inc Compositions and methods for modulating metabolic pathways
WO2013067485A1 (en) 2011-11-03 2013-05-10 University Of Florida Research Foundation, Inc. Nutritional supplement for weight management
ES2785094T3 (es) * 2011-11-21 2020-10-05 Emmaus Medical Inc Métodos y composiciones para el tratamiento de la diabetes y los síntomas relacionados
CN104302285A (zh) 2012-01-11 2015-01-21 雅培制药有限公司 用于治疗糖尿病性溃疡的β-羟基-β-甲基丁酸盐、精氨酸和谷氨酰胺的组合产品
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
AU2013312113B2 (en) 2012-09-10 2018-08-02 Metabolic Technologies, LLC Composition of HMB and ATP and methods of use
WO2014047493A1 (en) * 2012-09-21 2014-03-27 Abbott Laboratories Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate and protein
CN104780786A (zh) 2012-09-21 2015-07-15 雅培制药有限公司 包括β-羟基-β-甲基丁酸钙、蛋白质和低水平的电解质的营养组合物
JP6469015B2 (ja) 2012-11-13 2019-02-13 ニューサート サイエンシーズ， インコーポレイテッド エネルギー代謝を増大させるための組成物および方法
HK1220391A1 (zh) * 2013-03-14 2017-05-05 Abbott Laboratories 与长期体力活动不足有关的胰岛素抗性的治疗
US9585876B2 (en) 2013-03-15 2017-03-07 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
US20150057350A1 (en) * 2013-08-23 2015-02-26 Abbott Laboratories Fibrosis biomarkers and methods of using same
JP2017506651A (ja) 2014-02-27 2017-03-09 ニューサート サイエンシーズ， インコーポレイテッド 脂肪肝の低減または予防のための組成物および方法
US20160346238A1 (en) * 2015-06-01 2016-12-01 Metabolic Technologies, Inc. Compositions and Methods of Use of -hydroxy--methylbutyrate (HMB) for Decreasing Fat Mass
PL3349745T3 (pl) 2015-09-16 2024-05-20 Metabolic Technologies, LLC Kompozycje i sposoby stosowania beta-hydroksy-beta-metylomaślanu (hmb) w celu poprawy regeneracji po urazach tkanek miękkich
US12208073B2 (en) 2015-09-16 2025-01-28 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
CN108473411B (zh) * 2015-11-19 2022-08-12 协和发酵生化株式会社 3-羟基异戊酸的一价阳离子盐的晶体及该晶体的制造方法
BR112018014920A2 (en) 2016-01-21 2018-12-18 Metabolic Technologies, Inc. methods of modulating autophagy, treating or reducing the likelihood of onset of an autophagy-mediated condition, treating, inhibiting, reducing, decreasing, or preventing an age-related disorder, modulating the expression or activity of at least one factor transcription, treatment, prevention, reduction, inhibition or reduction of a pathological condition attributable to a state of nutrient excess, promoting longevity by modulating autophagy, increasing the length of time a mammal can lead a lifestyle active without suffering from conditions associated with aging and extending the health of a mammal.
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
SG11201809211QA (en) * 2016-04-19 2018-11-29 Keto Patent Group Inc Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
KR20190028441A (ko) 2016-06-24 2019-03-18 가부시키가이샤 오츠카 세이야쿠 고죠 3-히드록시이소발레르산의 아미노산염의 결정 및 그 제조 방법
PL3528801T3 (pl) 2016-10-21 2025-02-03 Metabolic Technologies, LLC Kompozycje i sposoby zastosowania beta-hydroksy-beta-metylomaślanu (hmb) i probiotyków
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
US10682325B2 (en) 2017-08-14 2020-06-16 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
MX2020007008A (es) * 2018-01-05 2021-04-28 Texas Tech Univ Office Of Research Commercialization COMPOSICIONES Y MÉTODOS DE USO DE ß- HIDROXI-ß-METILBUTIRATO (HMB) ASOCIADO CON AYUNO INTERMITENTE.
JP2021527670A (ja) 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 筋肉中の脂肪浸潤の治療のための組成物及び方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157022A (en) * 1989-11-22 1992-10-20 Adrian Barbul Method for reducing blood cholesterol using arginine
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
ES2142353T3 (es) * 1992-09-16 2000-04-16 Univ Iowa State Res Found Inc Procedimiento para reducir los niveles de colesterol total y de colesterol asociado a lipoproteinas de baja densidad en sangre.
US5348979A (en) * 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
WO1994017678A1 (en) * 1993-02-11 1994-08-18 Iowa State University Research Foundation, Inc. Method of enhancing nutritional value of colostrum and first milk of pregnant mammals
US5726146A (en) * 1994-12-06 1998-03-10 Natural Supplement Association, Incorporated Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
DE29707308U1 (de) * 1997-04-23 1997-06-26 Kunz, Armin, 66450 Bexbach Präparat zur Muskelerhaltung bzw. zur Förderung des Muskelaufbaus

Also Published As

Publication number Publication date
NO332374B1 (no) 2012-09-10
JP2012102118A (ja) 2012-05-31
US6031000A (en) 2000-02-29
EP1089726B1 (en) 2002-05-02
AU756353B2 (en) 2003-01-09
JP2002518440A (ja) 2002-06-25
ES2177293T3 (es) 2002-12-01
WO1999066917A2 (en) 1999-12-29
AU4708099A (en) 2000-01-10
DE69901396D1 (de) 2002-06-06
NO20101440L (no) 2001-02-20
PL195623B1 (pl) 2007-10-31
JP5690261B2 (ja) 2015-03-25
CA2334761A1 (en) 1999-12-29
JP5064609B2 (ja) 2012-10-31
NZ508395A (en) 2003-09-26
DK1089726T3 (da) 2002-07-22
EP1089726A2 (en) 2001-04-11
NO329914B1 (no) 2011-01-24
CA2334761C (en) 2009-04-28
WO1999066917A3 (en) 2000-04-20
NO20006633D0 (no) 2000-12-22
PL344589A1 (en) 2001-11-05
DE69901396T2 (de) 2002-08-29

Similar Documents

Publication Publication Date Title
NO20006633L (no) Preparat som omfatter &lt;beta&gt;-hydroksy-&lt;beta&gt;-metylsmörsyre og minst én aminosyre, og fremgangsmåter for anvendelse
DK0965578T3 (da) Hidtil ukendt triglycerik og præparat, som omfatter dette
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
NO20001102D0 (no) 2,3-diaryl-pyrazolo[1,5-B]pyridazinderivater, deres fremstilling og anvendelse som syklo-oksygenase 2 (COX-2) inhibitorer
NO307335B1 (no) Substituerte N-(indol-2-karbonyl)-&lt;beta&gt;-alaninamider, anvendelse derav og farmasøytisk preparat
NO20015859D0 (no) A-&lt;beta&gt;peptidpreparater og fremgangsmåter for fremstilling av slike
NO306401B1 (no) Oksazolidindionderivater, farmasöytisk preparat inneholdende slike derivater, og deres anvendelse
NO307707B1 (no) Spiroazabicykliske forbindelser, farmasøytisk preparat inneholdende slike forbindelser og anvendelse derav
NO20010078L (no) Fenoksyeddiksyrederivat og farmasøytisk sammensetning omfattende det samme
DK1216247T3 (da) Imidazoimidazoler og triazoler som anti-inflammatoriske midler
NO20004353L (no) Nye pyridazinderivater og medikamenter inneholdende disse som aktive ingredienser
DK1036794T3 (da) 2-Aryl-8-oxodihydropurinderivater, fremgangsmåde til fremstilling af samme, medicinske præparater indeholdende samme og mellemprodukter deraf
NO993868D0 (no) 3-piperidyl-4-oksokinazolin-derivater og medisinske preparater som inneholder slike
NO307049B1 (no) Forbindelse som er &lt;Beta&gt;-adrenergiske agonister, anvendelse derav og farmasøytisk blanding
NO994671D0 (no) Aryl- eller heteroarylsulfonamid-substituerte hydroksamsyrederivater, fremgangsmaate til fremstillint derav og deres anvendelse som farmasöytika
NO20005146D0 (no) Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
NO20003070L (no) Substituert tiazolidinderivat, fremgangsmÕte for fremstilling og anvendelse derav
NO981522L (no) Aminosyrederivater, deres fremstilling og anvendelse som endotelinantagonister
CY2006006I2 (el) Πρωτεϊνικα σκευασματα
NO20005173D0 (no) Gen som koder for heliomicin og anvendelse derav
NO20016247D0 (no) Streptograminderivater, deres fremstilling og preparater inneholdende derivatene
DK1124797T3 (da) N-Arylsulfonyl-aminosyre-omega-amider
NO951418D0 (no) Peptidderivater, deres fremstilling og anvendelse som terapeutika
NO970372D0 (no) Aroyloksy- og aroyltiopropanolamin-derivater anvendelige som &lt;beta&gt;-3-adrenoreseptor-agonister og antagonister for &lt;beta&gt;-1-og-&lt;beta&gt;-2-adrenoreseptorer og farmasöytiske blandinger derav
EE03387B1 (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks

Legal Events

Date Code Title Description
MK1K Patent expired